R&D Vaccine Factory
Invest with us in New vaccine and medicines R&D factory and become Shareholder
S-Pharma London U.K. - Investment in Biopharmaceutical
Research and development (R&D)
Company and activities that focus on the innovation of new products.
S-Pharma R&D for mRNA vaccine and smart medicines.
Discovering, developing and providing different branche of vaccines and medicines.
The development is due to complete in Q1 2022/Q3 2022
S-Pharma London U.K. are member of Sentange Group London U.K.
S-Pharma New Vaccine R&D Factory
Brand new Biopharmaceutical R&D (research & development) factory with vaccine and medicines factory.
- Type of business: Biopharmaceutical R&D (research & development) factory with vaccine and medicines factory.
- The development is due to complete in Q1 2022. or Q3 2022
- Location of Investment: European Union (EU)
- Full Investment (Capital cost): 246.000.000 € based on one R&D Factory for Vaccine and medicines.
- Holdings: Total of 24600 Share at 10.000 €.
- Min. investment 10.000 € for One share and One Voting Rights.
- Max. Investment 61..500.000 € for 25% Ownership and 6150 Share.
- One Share are One voting Rights.
- Vaccine factory stocks give additional income, or you can sell it at a higher price per share and earn from it as well.
- Our project report also maintains that will grow by over next five years with Up to 24% return pro year.
- Management team with record of success.
Ownership of shares (until now):
- S-Pharma U.K. own 6150 share (25% ownership)
- Live Insurance Company U.K own 2460 share (10% ownership)
- Private Investor own 2977 share (12,1%) (Investor from: Suisse, UK, USA, Russia, Germany, UAE, SA, China, Italy, Bahrain, Poland, Kuwait, Croatia, Spain, Israel, Netherland, Sweden, Norvege, Danemark and Island.
- Every Investor have "Memorandum and Articles of Association" and shareholder certify.
- One Share are One voting Rights.
- Project number: 888 048
In cooperation with S-Pharma London U.K.
Why Invest with us in R&D Vaccine Factory?
S-Pharma, a United Kingdom company for the manufacturing and sale of pharmaceutical products. Fully operational Pharmaceutical Production Facilities with all standards/certificates. Our project report also maintains that will grow by over next five years with Up to 24% return pro year.
- Vaccines are one of the greatest public health success stories in history.
- S-Pharma and its legacy companies and our partners have been working to discover and develop vaccines. Our vaccines have helped prevent a number of diseases, including ones never thought preventable. Today, we remain dedicated to the complex business of researching and producing vaccines.
- Now S-Pharma and our partners have been working to discover and develop coronavirus vaccines.
- BCG Vaccine: up to 10 mill/Year
- VARICELLA VACCINE: up to 10 mill/Year
- MMR VACCINE: up to 10 mill/Year
- DTP VACCINE: up to 10 mill/Year
- INFLUENCA VACCINE: up to 10 mill/Year
- PNEUMO VACCINE: up to 10 mill/Year
- ROTA VACCINE: up to 10 mill/Year
- EVAC (Ebola Vaccine): up to 10 mill/Year
- CORONAVIRUS VACCINE (COVID19) (in research & development process)
MEDICINES:
Consumer & Prescription medicine
- CHC – Consumer Healthcare
- Rx – Prescription medicine
Invest with us in New R&D Vaccine Factory
S-Pharma
- S-Pharma, a United Kingdom company for the manufacturing and sale of pharmaceutical products.
- Fully operational Pharmaceutical Production Facilities with all standards/certificates.
- The company manufactures and distributes high quality pharmaceutical products, generic prescription medications, and various non-prescription pharmaceutical products.
Vaccines, CHC, RX etc.
- Vaccines
- Medicines
- CHC – Consumer Healthcare
- Rx – Prescription medicine
Disinfection and Cleaning
- Disinfection and Cleaning in healthcare and nonhealthcare settings potentially contaminated with SARS-CoV-2 and other viruses and bacteries.